ClinicalTrials.gg
CompletedNCT05730465Updated Nov 16, 2026

Improving Blood Pressure Control in Stroke Patients by Increasing Access to a Home Blood Pressure Monitor

An interventional study of Use of Omron Home Blood Pressure Cuff in Hypertension, Stroke and TIA, sponsored by Stanford University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Stanford University · Not applicable, Interventional, and Prevention

How we know

Updated Nov 16, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Hypertension by Stanford University — 1 open to participants now, 2 under way, none of them phase 3. Hypertension · Stanford University.

Enrollment
12th of 14
37 · median 90
Started
2023
with 2 others
No phase
13 of 18
1 open now
Registered
17th of 18
by date

Among the 18 studies in Hypertension by Stanford University, this one is the 12th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2023, is one of 13 with no phase, and was the 17th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 18 studies in Hypertension by Stanford University is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Hypertension by Stanford University, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether providing teaching with a low-cost device can help to improve blood pressure, health outcomes, patient self-efficacy without exacerbating inequity between advantaged and disadvantaged patients.

The main question[s] it aims to answer are:

  1. Does providing a free home blood pressure cuff improve control of hypertension?
  2. Does providing a free home blood pressure cuff have a greater impact on control of hypertension in disadvantaged populations?
  3. Does improved control of home blood pressure decrease adverse patient outcomes?

Participants will be asked to

  • Take their blood pressure at home and records the results
  • Participate in follow-up phone calls from investigators at at 3 and 6 months

Researchers will compare patients provided with home blood pressure monitors to those who are provided with routine education

Read the detailed description

Patients with a history of hypertension and a history stroke (ischemic or hemorrhagic), transient ischemic attack (TIA), or otherwise are at high risk of stroke will be screened for enrollment.

Inclusion and exclusion criteria will be reviewed and confirmed by a member of the study team. If the patient meets criteria, the following will occur:

A member of the study team (physician, nurse, study coordinator) will describe the study to the patient and inform them of their candidacy. If the patient indicates interest in study participation, the patient will be provided a written or electronic consent form to review and sign. The patient will be randomized to one of two arms in the study.

Upon enrollment, the patient will complete an intake survey. Prior to hospital discharge, patients randomized to arm 1 (control) of the study will receive routine stroke discharge education which is standard of care. In addition to standard of care, a stroke nurse will provide and review with the patient a short informational pamphlet (included in the attachments) on the importance of blood pressure monitoring.

Patients randomized to arm 2 (intervention) will also receive this teaching as above. In addition, they will be given an Omron Home Blood Pressure Cuff furnished by the study. The nurse will provide additional education on on how to use the cuff, and how to record values in a blood pressure log.

At three months following enrollment, a member of the study team will call the patients in both arms to complete a questionnaire (included in the attachments) over the phone and provide a blood pressure reading using their home blood pressure cuff. If needed, a phone interpreter will be used.

At three months, patients randomized to arm 1 of the study will receive a blood pressure cuff in the mail with written instructions on how to use it.

At six months following enrollment, a member of the study team will call the patients in both arms to complete a questionnaire over the phone and provide a blood pressure reading using their home blood pressure cuff. If needed, a phone interpreter will be used.

The patient will be notified that the duration of their participation in the study has ended. All study materials given to the patient are theirs to keep.

A chart review will be conducted for the study participants to supply information about health outcomes incurred throughout the duration of the study, and to obtain blood pressure readings from ambulatory visits.

03

Conditions studied

  • Hypertension
  • Stroke
  • TIA
  • Vascular Diseases

Keywords

  • Hypertension
  • Stroke
  • TIA
  • Home blood pressure monitoring
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients over the age of 18 admitted to the Stanford Hospital (SHC) stroke service and discharging to home or acute rehab
  • Diagnosis of Ischemic Stroke, Hemorrhagic Stroke, (TIA), or otherwise deemed to be at increased risk of stroke by the treating team (for example, asymptomatic carotid stenosis).
  • No usable home blood pressure cuff available
  • Diagnosis of hypertension or elevated blood pressure (> 130/80) concerning to the treating clinician for hypertension
  • Participant or surrogate able to apply a home blood pressure cuff on the participant
  • Patient or Legally Authorized Representative (LAR) agree to participate and are able to consent.

Exclusion criteria

Exclusion Criteria:

  • Currently enrolled in another blood pressure or secondary prevention interventional research study
  • Upper arm circumference > 20 inches
  • Any other reason that, in the opinion of the investigator, makes the person a poor candidate for participation in this study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • No intervention
    Standard of Care

    Participants will receive routine stroke discharge education which is standard of care. A stroke nurse will provide and review with the patient a short informational pamphlet on the importance of blood pressure monitoring.

  • Experimental
    Access to Blood Pressure Monitoring

    Participants will also receive the teaching administered to the control group. In addition, they will be given an Omron Home Blood Pressure Cuff furnished by the study. The nurse will provide additional education on on how to use the cuff, and how to record values in a blood pressure log.

    Behavioral: Use of Omron Home Blood Pressure Cuff

Interventions

  • BehavioralUse of Omron Home Blood Pressure Cuff

    Use of an Omron Home Blood Pressure Cuff to monitor blood pressure after discharge

06

What researchers measure

Primary outcomes

  1. Blood pressure

    Home blood pressure measurements provided by patient at month 3

    Time frame: Month 3

  2. Blood pressure

    Home blood pressure measurements provided by patient at month 6

    Time frame: Month 6

Secondary outcomes

  1. Incidence of stroke

    Patient outcome

    Time frame: Months 3 and 6

  2. Incidence of TIA

    Patient outcome

    Time frame: Months 3 and 6

  3. Any hospitalization

    Patient outcome

    Time frame: Months 3 and 6

07

Study locations

1 site
08

References and documents

Publications

  • Ayala C, Tong X, Keenan NL. Regular use of a home blood pressure monitor by hypertensive adults--HealthStyles, 2005 and 2008. J Clin Hypertens (Greenwich). 2012 Mar;14(3):172-7. doi: 10.1111/j.1751-7176.2011.00582.x. Epub 2012 Jan 19. PubMed 22372777 ↗
  • Poon IO, Etti N, Lal LS. Does the use of home blood pressure monitoring vary by race, education, and income? Ethn Dis. 2010 Winter;20(1):2-6. PubMed 20178174 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Nov 2024, 18 months.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 18 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

Primary completion moved once since we started tracking on Sep 25, 2026: Jan 2025 → Nov 2024, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2023
First posted
Feb 15, 2023
StartActual
May 1, 2023
Primary completionActual
Nov 27, 2024was Jan 2025
CompletionActual
Apr 30, 2025
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 16, 2026
Primary completion
Jan 31, 2025→Nov 27, 2024 (actual)
Nov 16, 2026
Enrollment
50 (estimated)→37 (actual)
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Recruiting→Completed
    Primary completion Jan 31, 2025→Nov 27, 2024 (now actual)
    Enrollment 50 (estimated)→37 (actual)
    + 3 other changes: verification date, site details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05730465
Responsible party
Christina Mijalski (Clinical Assistant Professor, Stanford University) — Principal investigator
First posted
Feb 15, 2023
Start date
May 1, 2023
Primary completion
Nov 27, 2024
Completion
Apr 30, 2025
Last update
Nov 16, 2026

Study contacts

Liron D Kraler, MD
principal investigator · Stanford University
Christina M Mijalski Sells, MD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion